Delivery Order 75N93022D00016-75N93022F00001
Award Date 1/21/22
Potential Completion Date 1/13/32
Potential Value $2.2M
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost Plus Fixed Fee
Place of Performance
Frederick, MD 21702, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
6
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This contract award was issued by the Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corp. The $136,259.00 award is a delivery order under the Therapeutics Against Infectious Diseases Phase 1 contract, which funds a Phase 1 clinical trial unit for therapeutics against infectious diseases. The contract type is cost plus fixed fee, and there is no...
- This is a delivery order under a larger Therapeutics Against Infectious Diseases Phase 1 indefinite delivery/indefinite quantity (IDIQ) contract, awarded by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the U.S. Department of Health and Human Services (HHS). The $117,283 order provides base task funding to the prime contractor, Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation, for a Phase 1 clinical trial unit supporting the...
- This is a federal contract award with a potential value of $139,426.00, issued by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corp. The contract is a Delivery Order under the "Therapeutics Against Infectious Diseases Phase 1" master IDIQ contract. The award is for a PHASE 1 CLINICAL TRIAL UNIT FOR THERAPEUTICS AGAINST...
- This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corp. The $129,318.29 contract is a cost-plus-fixed-fee delivery order under the "Therapeutics Against Infectious Diseases Phase 1" contract vehicle, which funds Phase 1 clinical trials for infectious disease therapeutics. Dynport will provide a range of services including preclinical development,...
- This federal contract award to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corp, is in support of a Phase 1 Clinical Trial Unit for Therapeutics Against Infectious Diseases. The $1,757,807.36 ceiling value contract was awarded on August 19, 2016 by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services. The contract is a delivery order against the $30 million Preclinical Services for Biopharmaceutical...
- This delivery order, awarded on May 13, 2021, to Dynport Vaccine Company LLC (a General Dynamics subsidiary) by the National Institute of Allergy and Infectious Diseases (NIAID), provides $4.12 million under a cost-plus-fixed-fee structure to establish a Phase 1 Clinical Trial Unit for Therapeutics Against Infectious Diseases. The work is being performed in Frederick, Maryland, with an ultimate completion date of January 31, 2025. This delivery order is issued under the $346 million Early...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,500 firm fixed price delivery order contract to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation, for the Diagnostic Pre-Clinical Services Program. This contract is part of a larger Indefinite Delivery/Indefinite Quantity (IDIQ) contract vehicle that provides funding for development processes needed to bring candidate infectious disease diagnostics to market. Dynport has previous experience...
- This is a delivery order award to Dynport Vaccine Company LLC (DVC), a subsidiary of General Dynamics Corp, under the $36 million Diagnostic Pre-Clinical Services Program IDIQ contract with the National Institute of Allergy and Infectious Diseases (NIAID). The task order is for a 7-year period of performance with a ceiling value of $3,500. It does not have a set-aside designation. Under this contract, DVC will provide a range of research, development, manufacturing, and testing services to...
- This is a delivery order under the "Therapeutics Against Infectious Diseases Phase 1" indefinite delivery, indefinite quantity (IDIQ) contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services. The order, valued at $5,167,891.00, funds a Phase 1 clinical trial unit for therapeutic candidates against infectious diseases. The prime contractor is Dynport Vaccine Company LLC, a subsidiary of General...
- This is a $2,265,501.00 delivery order contract awarded to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation, by the National Institute of Allergy and Infectious Diseases (NIAID) under the Early Phase Clinical Trial Units (EPCTU) IDIQ contract vehicle. The contract is for cost plus fixed fee services to support early phase clinical trials, with a period of performance through July 15, 2025. The contract does not have a set-aside designation. Dynport Vaccine Company has...